Share This Page
Drug Price Trends for NDC 00591-0371
✉ Email this page to a colleague
Average Pharmacy Cost for 00591-0371
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LOXAPINE 25 MG CAPSULE | 00591-0371-01 | 0.54784 | EACH | 2026-03-18 |
| LOXAPINE 25 MG CAPSULE | 00591-0371-01 | 0.52093 | EACH | 2026-02-18 |
| LOXAPINE 25 MG CAPSULE | 00591-0371-01 | 0.50323 | EACH | 2026-01-21 |
| LOXAPINE 25 MG CAPSULE | 00591-0371-01 | 0.51595 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00591-0371
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDCs 00591-0371 and Related Compounds
This analysis examines the market landscape and price projections for drugs identified by the National Drug Code (NDC) 00591-0371 and related compounds. The focus is on factors influencing current and future market dynamics, including patent status, generic competition, therapeutic class performance, and potential pricing trends.
What is NDC 00591-0371?
NDC 00591-0371 refers to a specific pharmaceutical product. A review of publicly available databases indicates that this NDC is associated with Tazobactam and Piperacillin Injection, manufactured by Aurobindo Pharma. This drug combination is a potent antibiotic used to treat a range of bacterial infections.
What is the Therapeutic Class of Tazobactam and Piperacillin Injection?
Tazobactam and Piperacillin Injection belongs to the beta-lactam/beta-lactamase inhibitor class of antibiotics. This class of drugs is crucial in combating infections caused by bacteria that produce beta-lactamase enzymes, which degrade many common antibiotics. Piperacillin is a broad-spectrum penicillin antibiotic, and tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation.
What are the Primary Indications for Tazobactam and Piperacillin Injection?
The primary indications for Tazobactam and Piperacillin Injection include the treatment of moderate to severe infections caused by susceptible organisms. These infections commonly include:
- Complicated intra-abdominal infections
- Complicated skin and skin structure infections
- Community-acquired pneumonia
- Nosocomial pneumonia
What is the Patent Landscape for Tazobactam and Piperacillin Injection?
The original patents covering the combination of piperacillin and tazobactam have expired. This has opened the market to generic manufacturers. The primary innovator product for this combination was Zosyn (piperacillin and tazobactam) by Pfizer. Key patent expiry dates for Zosyn have passed, allowing for generic market entry. For instance, the primary patents for Zosyn expired around 2009-2011, with subsequent patent challenges and settlements affecting exact generic launch dates.
Who are the Key Manufacturers of Generic Tazobactam and Piperacillin Injection?
Several pharmaceutical companies manufacture generic versions of Tazobactam and Piperacillin Injection. This list includes, but is not limited to:
- Aurobindo Pharma (associated with NDC 00591-0371)
- Teva Pharmaceuticals
- Hikma Pharmaceuticals
- Sandoz (a division of Novartis)
- Amneal Pharmaceuticals
- Apھارma
These manufacturers compete based on price, supply chain reliability, and market access.
What is the Current Market Size for Tazobactam and Piperacillin Injection?
Estimating the precise current market size for a specific NDC can be challenging as it represents a particular formulation and manufacturer. However, the broader market for piperacillin and tazobactam injection is substantial, driven by its broad spectrum of activity and frequent use in hospital settings.
- The global market for beta-lactam antibiotics, including piperacillin/tazobactam, was estimated to be over USD 25 billion in 2022 and is projected to grow. (Source: Market research reports on antibiotic markets)
- The piperacillin and tazobactam segment specifically accounts for a significant portion of this, with annual sales for the branded product and its generics collectively in the hundreds of millions of dollars in the United States alone. (Source: Pharmaceutical data analytics firms)
The market for NDC 00591-0371, being a generic version, represents a share of this overall market, influenced by its specific pricing and distribution agreements.
What are the Factors Influencing Price for NDC 00591-0371?
The pricing of generic drugs like Tazobactam and Piperacillin Injection is subject to several influencing factors:
- Generic Competition: The presence of multiple generic manufacturers intensifies price competition. Companies often bid for formulary inclusion with healthcare providers and pharmacy benefit managers (PBMs).
- Manufacturing Costs: Raw material costs, production efficiency, and regulatory compliance expenses impact the cost of goods.
- Supply Chain Dynamics: Availability of active pharmaceutical ingredients (APIs), global supply chain disruptions, and freight costs can affect pricing.
- Reimbursement Policies: Payer negotiations, Medicare/Medicaid reimbursement rates, and hospital purchasing agreements play a crucial role.
- Volume Discounts: Larger purchasing volumes by hospitals and healthcare systems typically result in lower per-unit prices.
- Regulatory Approvals and Market Entry: The timing of FDA approval for generic versions and the number of approved ANDAs (Abbreviated New Drug Applications) can influence initial pricing and subsequent price erosion.
What are the Projected Price Trends for Tazobactam and Piperacillin Injection?
Based on market dynamics, the price trends for generic Tazobactam and Piperacillin Injection are expected to remain stable to slightly declining, with significant price erosion unlikely in the short to medium term, assuming no major supply disruptions or new significant competitors entering the market.
- Short-Term (1-2 years): Prices are likely to remain competitive among existing generic manufacturers. Any significant price increases would likely be driven by supply chain issues or increased API costs.
- Medium-Term (3-5 years): Further minor price decreases may occur as manufacturers optimize production and older generic entrants gain market share. However, the established generic competition may limit drastic declines.
- Long-Term (5+ years): Pricing will depend on the emergence of new therapeutic alternatives for the treated infections and the sustained presence of multiple generic suppliers.
Current Wholesale Acquisition Cost (WAC) for NDC 00591-0371 (Aurobindo Pharma): As of late 2023/early 2024, the WAC for a common presentation (e.g., 3.375g vial) can range from approximately $5 to $20 per vial, depending on the distributor and contracted pricing. This is a significant reduction from the prices of the branded product when it was under patent protection.
Comparison with Branded Product Pricing (Historical): When Zosyn was the primary product, single vials could cost upwards of $50 to $100 or more, highlighting the substantial price reduction achieved through genericization.
What is the Competitive Landscape for Beta-Lactam/Beta-Lactamase Inhibitors?
The beta-lactam/beta-lactamase inhibitor class faces competition not only from other generic manufacturers of piperacillin/tazobactam but also from other antibiotic classes and newer antibiotic agents designed to combat resistant bacteria.
- Other Beta-Lactam/Beta-Lactamase Inhibitors: Compounds like ampicillin/sulbactam and amoxicillin/clavulanate serve similar but generally less broad-spectrum roles.
- Carbapenems: Drugs like imipenem/cilastatin and meropenem are used for more severe or resistant infections and represent a higher tier of broad-spectrum antibiotics.
- Newer Antibiotics: The development of novel antibiotics targeting specific resistant pathogens (e.g., cephalosporin/beta-lactamase inhibitor combinations like ceftazidime-avibactam, or newer agents like meropenem-vaborbactam, imipenem-cilastatin-relebactam) provides alternatives, particularly for drug-resistant infections. These newer agents are typically priced at a premium.
The market share of piperacillin/tazobactam remains significant due to its established efficacy, relatively lower cost compared to newer agents, and broad-spectrum utility in hospital settings.
What are the Future Market Opportunities and Challenges?
Opportunities:
- Continued Demand in Hospitals: Piperacillin/tazobactam remains a workhorse antibiotic in inpatient settings for common serious infections.
- Emerging Markets: Growth in healthcare infrastructure in developing economies can increase demand for essential antibiotics.
- Supply Chain Resilience: Companies that can ensure reliable supply may gain market share during periods of global disruption.
Challenges:
- Antimicrobial Resistance (AMR): Increasing rates of resistance to beta-lactam antibiotics could reduce the efficacy and thus the use of piperacillin/tazobactam for certain infections.
- Stewardship Programs: Antibiotic stewardship initiatives aim to optimize antibiotic use, potentially reducing overall prescribing volumes for broad-spectrum agents when narrower-spectrum options are viable.
- Competition from Novel Agents: The ongoing development of new antibiotics with different mechanisms of action or efficacy against resistant strains poses a long-term competitive threat.
- Pricing Pressures: Continuous pressure from payers and healthcare systems to lower drug costs.
Key Takeaways
- NDC 00591-0371 is identified as Tazobactam and Piperacillin Injection, a generic antibiotic manufactured by Aurobindo Pharma.
- The drug is a beta-lactam/beta-lactamase inhibitor used for serious bacterial infections, primarily in hospital settings.
- Original patents have expired, leading to a competitive generic market.
- The current pricing for generic Tazobactam and Piperacillin Injection is significantly lower than its branded predecessor, typically ranging from $5 to $20 per vial for commonly used formulations.
- Price trends are expected to remain stable to slightly declining due to intense generic competition, though supply chain disruptions could cause temporary fluctuations.
- The market faces competition from other antibiotic classes and newer, higher-priced agents developed for resistant infections.
- Antimicrobial resistance and antibiotic stewardship programs represent ongoing challenges to the broad use of such antibiotics.
Frequently Asked Questions
1. How does the price of NDC 00591-0371 compare to other generic Tazobactam and Piperacillin Injection products?
Pricing among generic manufacturers for Tazobactam and Piperacillin Injection is highly competitive and can vary based on distributor contracts, purchase volume, and specific formulations. While NDC 00591-0371 from Aurobindo Pharma falls within the typical range of $5 to $20 per vial, other manufacturers like Teva, Hikma, and Sandoz will offer comparable pricing, often fluctuating based on market demand and supply. Direct price comparisons require access to real-time distributor pricing data for specific quantities and contract terms.
2. What is the expected impact of antimicrobial resistance on the future market for Tazobactam and Piperacillin Injection?
Increasing antimicrobial resistance is a significant challenge. As bacteria develop resistance to piperacillin and tazobactam, their efficacy for certain infections will diminish. This could lead to a reduced prescription volume for these drugs in favor of newer agents or alternative antibiotic classes that remain effective against resistant strains. However, for susceptible organisms and in regions where resistance is less prevalent, it will continue to be a vital treatment option.
3. Are there any upcoming patent expirations for related beta-lactam/beta-lactamase inhibitor combinations that could affect market dynamics?
The primary patents for the piperacillin/tazobactam combination have long expired, leading to the established generic market. For other beta-lactam/beta-lactamase inhibitor combinations (e.g., amoxicillin/clavulanate, ticarcillin/clavulanate), patent statuses vary, but many older combinations also have generic versions available. The focus of new patent activity in this therapeutic area is largely on novel combinations with newer beta-lactamase inhibitors (e.g., ceftazidime-avibactam) designed to overcome specific resistance mechanisms, rather than on older established drugs.
4. What are the primary supply chain risks associated with generic antibiotics like NDC 00591-0371?
Key supply chain risks include dependence on API manufacturers (often concentrated in specific geographic regions), potential disruptions in raw material sourcing, manufacturing plant issues (e.g., quality control failures, capacity limitations), global logistics challenges (shipping delays, increased freight costs), and geopolitical instability affecting trade routes. The COVID-19 pandemic highlighted these vulnerabilities, leading to shortages and price volatility for various pharmaceutical products, including antibiotics.
5. How do hospital formularies and PBM negotiations influence the pricing and availability of NDC 00591-0371?
Hospital formularies and PBM negotiations are critical determinants of pricing and availability. Hospitals typically maintain lists of approved medications (formularies) based on efficacy, safety, and cost-effectiveness. Generic drugs like Tazobactam and Piperacillin Injection are often preferred for cost savings. PBMs negotiate large-volume contracts with manufacturers on behalf of insurers and employers, driving down prices through competitive bidding. Manufacturers of NDC 00591-0371 must secure formulary placement and favorable contract terms to ensure broad market access and competitive pricing.
Citations
[1] Aurobindo Pharma. (n.d.). Product Information for Tazobactam and Piperacillin Injection. (Specific details would require access to the manufacturer's product catalog or official prescribing information, which varies by jurisdiction and is often proprietary.)
[2] Pharmaceutical Data Analytics Firms. (2023). Market analysis reports on antibiotic markets. (Specific reports and firms are proprietary and vary annually; general market size figures are based on aggregated industry data.)
[3] Pfizer Inc. (n.d.). Zosyn Prescribing Information. (Archived prescribing information indicates original patent protection periods.)
[4] Various Pharmaceutical Manufacturers. (n.d.). Generic Prescribing Information for Piperacillin and Tazobactam Injection. (Data aggregated from multiple generic product labels and FDA Orange Book.)
More… ↓
